376 related articles for article (PubMed ID: 22884399)
21. Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema.
Server A; Kulle B; Maehlen J; Josefsen R; Schellhorn T; Kumar T; Langberg CW; Nakstad PH
Acta Radiol; 2009 Jul; 50(6):682-9. PubMed ID: 19449234
[TBL] [Abstract][Full Text] [Related]
22. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients.
Kim JY; Park JE; Jo Y; Shim WH; Nam SJ; Kim JH; Yoo RE; Choi SH; Kim HS
Neuro Oncol; 2019 Feb; 21(3):404-414. PubMed ID: 30107606
[TBL] [Abstract][Full Text] [Related]
23. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma.
Tsien C; Galbán CJ; Chenevert TL; Johnson TD; Hamstra DA; Sundgren PC; Junck L; Meyer CR; Rehemtulla A; Lawrence T; Ross BD
J Clin Oncol; 2010 May; 28(13):2293-9. PubMed ID: 20368564
[TBL] [Abstract][Full Text] [Related]
24. Gliomas: Histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted MR imaging--correlation with tumor grade.
Kang Y; Choi SH; Kim YJ; Kim KG; Sohn CH; Kim JH; Yun TJ; Chang KH
Radiology; 2011 Dec; 261(3):882-90. PubMed ID: 21969667
[TBL] [Abstract][Full Text] [Related]
25. Direct measurement of the signal intensity of diffusion-weighted magnetic resonance imaging for preoperative grading and treatment guidance for brain gliomas.
Wu CC; Guo WY; Chen MH; Ho DM; Hung AS; Chung HW
J Chin Med Assoc; 2012 Nov; 75(11):581-8. PubMed ID: 23158036
[TBL] [Abstract][Full Text] [Related]
26. Pseudoprogression following concurrent temozolomide and radiotherapy in a patient with glioblastoma: findings on functional imaging techniques.
Shirakawa Y; Yoshiura T; Hiwatashi A; Yamashita K; Kamano H; Shioyama Y; Abe K; Amano T; Nakamizo A; Yoshimoto K; Honda H; Torisu R; Suzuki S; Honda H
Fukuoka Igaku Zasshi; 2010 Dec; 101(12):257-64. PubMed ID: 21476455
[TBL] [Abstract][Full Text] [Related]
27. Post-radiotherapy apparent diffusion coefficient (ADC) in children and young adults with high-grade gliomas and diffuse intrinsic pontine gliomas.
Carceller F; Jerome NP; Fowkes LA; Khabra K; Mackinnon A; Bautista F; Marshall LV; Vaidya S; Mandeville H; Morgan V; Leach MO; Koh DM
Pediatr Hematol Oncol; 2019 Mar; 36(2):103-112. PubMed ID: 30978130
[No Abstract] [Full Text] [Related]
28. Parametric Response Mapping of Apparent Diffusion Coefficient as an Imaging Biomarker to Distinguish Pseudoprogression from True Tumor Progression in Peptide-Based Vaccine Therapy for Pediatric Diffuse Intrinsic Pontine Glioma.
Ceschin R; Kurland BF; Abberbock SR; Ellingson BM; Okada H; Jakacki RI; Pollack IF; Panigrahy A
AJNR Am J Neuroradiol; 2015 Nov; 36(11):2170-6. PubMed ID: 26338910
[TBL] [Abstract][Full Text] [Related]
29. Glioma grading using apparent diffusion coefficient map: application of histogram analysis based on automatic segmentation.
Lee J; Choi SH; Kim JH; Sohn CH; Lee S; Jeong J
NMR Biomed; 2014 Sep; 27(9):1046-52. PubMed ID: 25042540
[TBL] [Abstract][Full Text] [Related]
30. Hypercellularity Components of Glioblastoma Identified by High b-Value Diffusion-Weighted Imaging.
Pramanik PP; Parmar HA; Mammoser AG; Junck LR; Kim MM; Tsien CI; Lawrence TS; Cao Y
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):811-9. PubMed ID: 26104935
[TBL] [Abstract][Full Text] [Related]
31. Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide.
Topkan E; Topuk S; Oymak E; Parlak C; Pehlivan B
Am J Clin Oncol; 2012 Jun; 35(3):284-9. PubMed ID: 21399487
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Wick W; Chinot OL; Bendszus M; Mason W; Henriksson R; Saran F; Nishikawa R; Revil C; Kerloeguen Y; Cloughesy T
Neuro Oncol; 2016 Oct; 18(10):1434-41. PubMed ID: 27515827
[TBL] [Abstract][Full Text] [Related]
33. Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53.
Kang HC; Kim CY; Han JH; Choe GY; Kim JH; Kim JH; Kim IA
J Neurooncol; 2011 Mar; 102(1):157-62. PubMed ID: 20632071
[TBL] [Abstract][Full Text] [Related]
34. Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas.
Baek HJ; Kim HS; Kim N; Choi YJ; Kim YJ
Radiology; 2012 Sep; 264(3):834-43. PubMed ID: 22771885
[TBL] [Abstract][Full Text] [Related]
35. Intravoxel incoherent motion diffusion-weighted MR imaging of gliomas: efficacy in preoperative grading.
Hu YC; Yan LF; Wu L; Du P; Chen BY; Wang L; Wang SM; Han Y; Tian Q; Yu Y; Xu TY; Wang W; Cui GB
Sci Rep; 2014 Dec; 4():7208. PubMed ID: 25434593
[TBL] [Abstract][Full Text] [Related]
36. The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping.
Bulik M; Kazda T; Slampa P; Jancalek R
Biomed Res Int; 2015; 2015():641023. PubMed ID: 26448943
[TBL] [Abstract][Full Text] [Related]
37. Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI.
Wang S; Martinez-Lage M; Sakai Y; Chawla S; Kim SG; Alonso-Basanta M; Lustig RA; Brem S; Mohan S; Wolf RL; Desai A; Poptani H
AJNR Am J Neuroradiol; 2016 Jan; 37(1):28-36. PubMed ID: 26450533
[TBL] [Abstract][Full Text] [Related]
38. Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence.
Prager AJ; Martinez N; Beal K; Omuro A; Zhang Z; Young RJ
AJNR Am J Neuroradiol; 2015 May; 36(5):877-85. PubMed ID: 25593202
[TBL] [Abstract][Full Text] [Related]
39. Peritumoral brain regions in gliomas and meningiomas: investigation with isotropic diffusion-weighted MR imaging and diffusion-tensor MR imaging.
Provenzale JM; McGraw P; Mhatre P; Guo AC; Delong D
Radiology; 2004 Aug; 232(2):451-60. PubMed ID: 15215555
[TBL] [Abstract][Full Text] [Related]
40. Use of a high b-value for diffusion weighted imaging of peritumoral regions to differentiate high-grade gliomas and solitary metastases.
Han C; Huang S; Guo J; Zhuang X; Han H
J Magn Reson Imaging; 2015 Jul; 42(1):80-6. PubMed ID: 25223489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
